Testing two doses of carfilzomib with dexamethasone for relapsed or refractory multiple myeloma

What we are studying

The purpose of this study is to find out what effects, good and/or bad, adding the drug carfilzomib to regular treatment with dexamethasone has on you and your disease. Researchers would like to compare a higher dose of carfilzomib to the lower dose that is usually used to find out which is better. The lower dose of carfilzomib is approved for treatment of your cancer. The higher dose is experimental. Therefore, carfilzomib is experimental for this study.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Study participants must have had at least 1 prior regimen of chemotherapy.

What is involved

  • Study participants will receive chemotherapy for as long as they can tolerate the treatment or until their cancer returns.



Contact Information

Study Coordinator
Scarlett Hutchens

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.